Cancer Family
Malignant Soft Tissue Neoplasm
CI-CAN-00000251Explore in graph →
341 active trials9 approved drugs37 evidence items
- NCIt
- C4867
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000251Explore in graph →
Clinical trials
1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (200)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03993106 | A Study of sEphB4-HSA in Kaposi Sarcoma | unknown | Phase 2 | 65 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05189483 |
| Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. |
| unknown |
| Phase 2 |
| 40 |
| Henan Cancer HospitalOTHER_GOV |
| 1 |
| Feb 7, 2024 |
| clinicaltrials |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma(ACCeSs) | terminated | Phase 2 | 3 | Italian Sarcoma GroupNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05154630 | Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors | terminated | Phase 1 / Phase 2 | 8 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT01755195 | Cabozantinib for Adults With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04589754 | Adriamycin and Ifosfamide Combined With Sintilimab | unknown | Phase 2 | 176 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04118166 | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | completed | Phase 2 | 30 | Kristen GanjooOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT03056001 | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | completed | Phase 2 | 30 | Wake Forest University Health SciencesOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02584309 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 73 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT00019968 | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 0 | Oct 31, 2023 | clinicaltrials |
| NCT06074692 | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)(PRIMA) | recruiting | Phase 2 | 86 | Ruijin HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03063632 | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT05448820 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | unknown | Phase 1 / Phase 2 | 15 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | withdrawn | Phase 2 | 0 | David Liebner, MDOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | terminated | Phase 1 / Phase 2 | 23 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 13, 2023 | clinicaltrials |
| NCT01719744 | Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05961761 | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients(PROPANE) | recruiting | Phase 2 | 80 | Niels JunkerOTHER | 3 | Jul 27, 2023 | clinicaltrials |
| NCT03317457 | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma(MEDISARC) | completed | Phase 2 | 103 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT02275286 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients(TRASTS) | recruiting | Phase 1 / Phase 2 | 199 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | May 31, 2023 | clinicaltrials |
| NCT04593758 | To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue | completed | Phase 1 / Phase 2 | 16 | Cornerstone PharmaceuticalsINDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT02494570 | A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa(AMPECT) | completed | Phase 2 | 34 | Aadi Bioscience, Inc.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT02066285 | Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma | completed | Phase 2 | 96 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04138381 | Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)(SeliGIST) | unknown | Phase 1 / Phase 2 | 30 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT05131386 | Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas(SYNERGIAS) | unknown | Phase 2 | 85 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05656144 | Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma | unknown | Phase 2 | 49 | Peking University Cancer Hospital & InstituteOTHER | 0 | Dec 19, 2022 | clinicaltrials |
| NCT05302570 | Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS(PROTONS-RPS) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT03590210 | Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas(NiTraSarc) | completed | Phase 2 | 92 | University Medicine GreifswaldOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05602415 | Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma | unknown | Phase 2 | 41 | Ruijin HospitalOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT01495598 | Pomalidomide for Kaposi Sarcoma in People With or Without HIV | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Nov 1, 2022 | clinicaltrials |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | terminated | Phase 2 | 5 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02987959 | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | terminated | Phase 2 | 6 | Fox Chase Cancer CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00140855 | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma | terminated | Phase 2 | 6 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01389050 | High Precision RT For Soft-Tissue Sarcoma | completed | Phase 2 | 26 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03524898 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | terminated | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04012827 | Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma | unknown | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05518526 | Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases(ANNA-SARC) | unknown | Phase 1 / Phase 2 | 64 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT01462630 | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | completed | Phase 2 | 29 | Fox Chase Cancer CenterOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT04065152 | Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma(KAPVEC) | unknown | Phase 2 | 20 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | completed | Phase 2 | 178 | Northwestern UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
Data updated 22 days agoSource updated May 2, 2024source: clinicaltrials